Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Is ICER Too NICE? A Comparison Of Drug Assessments Programs

Dec 23 2016

• By Cathy Kelly

Related Content

Hepatitis C Pricing: Insurers' Cost Benchmarks Would Yield Optimal Price Of $42,000 – Report

Nov 20 2014

Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza

Oct 21 2015

NICE Reassessing Old CDF Drugs On Value-For-Money Basis – Some Fail

Aug 22 2016

NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut

Nov 17 2016

Psoriasis Drug Valuation By ICER May Undercut Routine Step Therapy

Dec 09 2016

ICER Eyes QALY Ratios, Budget Impacts In Methods Review

Jul 28 2016

Intercept's Pricing Of Ocaliva Anticipates Outcomes Data

May 31 2016

ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer

Aug 23 2016

Related Companies

Gilead Sciences, Inc.

Roche Holding AG

Intercept Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Eli Lilly and Company

GSK plc

Johnson & Johnson

Additional Topics

United States Health Technology Assessment Market Access Policy Pricing Debate Pricing Strategies Reimbursement BioPharmaceutical

More from Health Technology Assessment

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window